Oncobit secures CHF 1.47M in Pre-Series A Round to advance precision cancer solutions
22.11.2024
Swiss-based precision medicine company Oncobit has raised CHF 1.47 million in its Pre-Series A financing round. The funds will support the company's product development initiatives and growth strategy, strengthening its focus on delivering advanced solutions in cancer care.
 Oncobit's team
|
 |
Venturelab alumnus Oncobit, a Swiss company specializing in cancer precision medicine, has announced the completion of a Pre-Series A financing round, securing CHF 1.47 million. The round saw participation from existing and new investors, reflecting confidence in Oncobit's approach and growth potential in the advancing field of liquid biopsy-based cancer monitoring.
The funds will be used to advance clinical melanoma research, expand Oncobit's monitoring platform to include colorectal cancer, and pursue new partnerships and market opportunities, including entry into the US. This investment equips the company to sustain its growth and strengthen its position in the cancer monitoring sector.
Oncobit participated in Venture Leaders Medtech and won the final stage of Venture Kick in 2022.
The funds will be used to advance clinical melanoma research, expand Oncobit's monitoring platform to include colorectal cancer, and pursue new partnerships and market opportunities, including entry into the US. This investment equips the company to sustain its growth and strengthen its position in the cancer monitoring sector.
Oncobit participated in Venture Leaders Medtech and won the final stage of Venture Kick in 2022.